S&P 500   3,134.66 (+0.07%)
DOW   27,839.77 (-0.15%)
QQQ   204.32 (+0.21%)
FB   200.96 (+0.04%)
MSFT   151.02 (-0.08%)
GOOGL   1,341.58 (-0.10%)
AMZN   1,738.27 (-0.05%)
CGC   20.16 (+0.35%)
NVDA   215.95 (+0.92%)
MU   48.85 (+2.93%)
GE   10.99 (-0.18%)
T   38.06 (+0.00%)
F   9.12 (+0.55%)
BAC   33.67 (+0.42%)
GILD   67.85 (+1.15%)
S&P 500   3,134.66 (+0.07%)
DOW   27,839.77 (-0.15%)
QQQ   204.32 (+0.21%)
FB   200.96 (+0.04%)
MSFT   151.02 (-0.08%)
GOOGL   1,341.58 (-0.10%)
AMZN   1,738.27 (-0.05%)
CGC   20.16 (+0.35%)
NVDA   215.95 (+0.92%)
MU   48.85 (+2.93%)
GE   10.99 (-0.18%)
T   38.06 (+0.00%)
F   9.12 (+0.55%)
BAC   33.67 (+0.42%)
GILD   67.85 (+1.15%)
S&P 500   3,134.66 (+0.07%)
DOW   27,839.77 (-0.15%)
QQQ   204.32 (+0.21%)
FB   200.96 (+0.04%)
MSFT   151.02 (-0.08%)
GOOGL   1,341.58 (-0.10%)
AMZN   1,738.27 (-0.05%)
CGC   20.16 (+0.35%)
NVDA   215.95 (+0.92%)
MU   48.85 (+2.93%)
GE   10.99 (-0.18%)
T   38.06 (+0.00%)
F   9.12 (+0.55%)
BAC   33.67 (+0.42%)
GILD   67.85 (+1.15%)
S&P 500   3,134.66 (+0.07%)
DOW   27,839.77 (-0.15%)
QQQ   204.32 (+0.21%)
FB   200.96 (+0.04%)
MSFT   151.02 (-0.08%)
GOOGL   1,341.58 (-0.10%)
AMZN   1,738.27 (-0.05%)
CGC   20.16 (+0.35%)
NVDA   215.95 (+0.92%)
MU   48.85 (+2.93%)
GE   10.99 (-0.18%)
T   38.06 (+0.00%)
F   9.12 (+0.55%)
BAC   33.67 (+0.42%)
GILD   67.85 (+1.15%)
Log in

NASDAQ:RTTR - Ritter Pharmaceuticals Stock Price, Forecast & News

$0.18
+0.01 (+5.88 %)
(As of 12/11/2019 12:49 PM ET)
Today's Range
$0.18
Now: $0.18
$0.20
50-Day Range
$0.17
MA: $0.22
$0.29
52-Week Range
$0.16
Now: $0.18
$1.35
Volume20,802 shs
Average Volume620,663 shs
Market Capitalization$1.83 million
P/E RatioN/A
Dividend YieldN/A
Beta1.02
Ritter Pharmaceuticals, Inc develops and sells novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b clinical trial for the reduction of symptoms associated with lactose intolerance. The company's product, RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RTTR
CUSIPN/A
Phone310-203-1000

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.22 per share

Profitability

Net Income$-16,870,000.00

Miscellaneous

Employees7
Market Cap$1.83 million
Next Earnings Date4/3/2020 (Estimated)
OptionableNot Optionable

Receive RTTR News and Ratings via Email

Sign-up to receive the latest news and ratings for RTTR and its competitors with MarketBeat's FREE daily newsletter.


Ritter Pharmaceuticals (NASDAQ:RTTR) Frequently Asked Questions

What is Ritter Pharmaceuticals' stock symbol?

Ritter Pharmaceuticals trades on the NASDAQ under the ticker symbol "RTTR."

When did Ritter Pharmaceuticals' stock split? How did Ritter Pharmaceuticals' stock split work?

Ritter Pharmaceuticals shares reverse split on the morning of Friday, March 23rd 2018. The 1-10 reverse split was announced on Thursday, March 22nd 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, March 22nd 2018. An investor that had 100 shares of Ritter Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

How were Ritter Pharmaceuticals' earnings last quarter?

Ritter Pharmaceuticals Inc (NASDAQ:RTTR) released its quarterly earnings results on Wednesday, November, 13th. The biotechnology company reported ($0.23) earnings per share for the quarter, meeting the consensus estimate of ($0.23). View Ritter Pharmaceuticals' Earnings History.

When is Ritter Pharmaceuticals' next earnings date?

Ritter Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Friday, April 3rd 2020. View Earnings Estimates for Ritter Pharmaceuticals.

What is the consensus analysts' recommendation for Ritter Pharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ritter Pharmaceuticals in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Ritter Pharmaceuticals.

Has Ritter Pharmaceuticals been receiving favorable news coverage?

Press coverage about RTTR stock has trended somewhat positive recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Ritter Pharmaceuticals earned a coverage optimism score of 2.0 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for Ritter Pharmaceuticals.

Are investors shorting Ritter Pharmaceuticals?

Ritter Pharmaceuticals saw a drop in short interest in November. As of November 15th, there was short interest totalling 318,500 shares, a drop of 44.4% from the October 31st total of 572,800 shares. Based on an average daily volume of 978,000 shares, the days-to-cover ratio is currently 0.3 days. Approximately 3.5% of the company's shares are short sold. View Ritter Pharmaceuticals' Current Options Chain.

Who are some of Ritter Pharmaceuticals' key competitors?

What other stocks do shareholders of Ritter Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ritter Pharmaceuticals investors own include Endologix (ELGX), Aegean Marine Petroleum Network (ANW), Chipotle Mexican Grill (CMG), Apache (APA), Charles Schwab (SCHW), Genocea Biosciences (GNCA), Hudson Technologies (HDSN), Vicor (VICR), Zoetis (ZTS) and CARBO Ceramics (CRR).

Who are Ritter Pharmaceuticals' key executives?

Ritter Pharmaceuticals' management team includes the folowing people:
  • Mr. Ira Eliot Ritter, Co-Founder, Exec. Chairman & Chief Strategic Officer (Age 70)
  • Mr. Andrew J. Ritter, Co-Founder, CEO, Pres, Corp. Sec. & Director (Age 36)
  • Mr. Michael D. Step, Consultant & Director (Age 59)
  • Mr. John W. Beck CPA, CPA, Chief Financial Officer (Age 59)
  • Ms. Ellen F. Mochizuki, Consultant (Age 52)

When did Ritter Pharmaceuticals IPO?

(RTTR) raised $20 million in an initial public offering on Wednesday, June 24th 2015. The company issued 4,000,000 shares at a price of $5.00 per share. Aegis Capital Corp and Chardan Capital Markets acted as the underwriters for the IPO and Barrington Research was co-manager.

How do I buy shares of Ritter Pharmaceuticals?

Shares of RTTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Ritter Pharmaceuticals' stock price today?

One share of RTTR stock can currently be purchased for approximately $0.18.

How big of a company is Ritter Pharmaceuticals?

Ritter Pharmaceuticals has a market capitalization of $1.83 million. The biotechnology company earns $-16,870,000.00 in net income (profit) each year or ($3.66) on an earnings per share basis. Ritter Pharmaceuticals employs 7 workers across the globe.View Additional Information About Ritter Pharmaceuticals.

What is Ritter Pharmaceuticals' official website?

The official website for Ritter Pharmaceuticals is http://www.ritterpharmaceuticals.com/.

How can I contact Ritter Pharmaceuticals?

Ritter Pharmaceuticals' mailing address is 1880 CENTURY PARK EAST SUITE 1000, LOS ANGELES CA, 90067. The biotechnology company can be reached via phone at 310-203-1000 or via email at [email protected]


MarketBeat Community Rating for Ritter Pharmaceuticals (NASDAQ RTTR)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  260 (Vote Outperform)
Underperform Votes:  228 (Vote Underperform)
Total Votes:  488
MarketBeat's community ratings are surveys of what our community members think about Ritter Pharmaceuticals and other stocks. Vote "Outperform" if you believe RTTR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RTTR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/11/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel